India’s Health Ministry has announced a big change: drugs approved in the United States, Japan, or the United Kingdom will no longer need clinical trials in India. This decision is meant to make medicines and vaccines more available and affordable in the country.
Currently, clinical trials can delay the availability of new drugs by 5 to 20 years. Pharmaceutical companies have been asking for this change for a long time.
Apurva Chandra, the Secretary of the Health Ministry, said that previously, all foreign medicines needed clinical trials in India, which made critical medicines arrive much later. This also kept foreign companies from entering the Indian market. The new rule is expected to improve the availability of medicines in India.
According to the New Drug Approval and Clinical Trial Rules 2019, Rule 101, drugs from countries like the US, UK, Japan, Australia, Canada, and the EU can now be exempt from trials in India for:
– Medicines for rare diseases
– Gene and cell therapy products
– New medicines used during pandemics
– New medicines for special defense needs
This change is expected to increase the availability of cancer and rare disease medicines in India. It should also lower costs. Dr. Rajeev Singh Raghuvanshi, the Drugs Controller General of India, has issued new orders for drug companies based on this decision.
